Clearmind Medicine has, and continues to build, a culture of world-leading innovators in novel psychedelics. Learn more about the team we’ve created so far.

Dr. Adi Zuloff-Shani is a Biomedical Research and Development Executive with a vast experience with over 20 years of strategic and operational leadership in the healthcare industry and a deep understanding of therapeutics development in heavily regulated environments.

Previously the Executive Director of MAPS (Multidisciplinary Association for Psychedelic Studies) Canada for 10 years, Mark is an adjunct professor at the University of British Columbia School of Population and Public Health and has published on the issue of drug control policy and psychedelics. Mark also worked in the addictions field in counseling, supervisory and management positions for 28 years. Mark has provided public education on drugs and drug policy for over 30 years.